Department of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Front Immunol. 2022 Apr 13;13:869993. doi: 10.3389/fimmu.2022.869993. eCollection 2022.
Transcatheter arterial chemoembolization LIHC, Liver hepatocellular carcinoma; (TACE) is a valid therapeutic method for hepatocellular carcinoma (HCC). However, many patients respond poorly to TACE, thus leading to an adverse outcome. Therefore, finding new biomarkers for forecasting TACE refractoriness occurrence and prognosis becomes one of the current research priorities in the field of HCC treatment.
Based on microarray datasets and a high-throughput sequencing dataset, the TACE refractoriness-related genes (TRGs) were identified by differential expression analysis. LASSO and Cox regression were applied to construct TACE refractoriness diagnostic score (TRD score) and prognostic score (TRP score) and validated their accuracy in external datasets. Functional correlation of TRP score was analyzed by gene set variation analysis and Gene Ontology. CIBERSORT and IMMUNCELL AI algorithms were performed to understand the correlation between the two scores and immune activity. We further carried out the efficacy analysis of immunotherapy and targeted drugs in the different TRP score groups. Furthermore, a nomogram was built by integrating various independent prognostic factors and validated its effectiveness in different datasets.
We identified 487 TRGs combined with GSE104580 and TCGA datasets. Then four novel TRGs (TTK, EPO, SLC7A11, and PON1) were screened out to construct TRD score and TRP score models, and both two scores had good predictive ability in external datasets. Tumors with high TRP score show an immunosuppressive phenotype with more infiltrations of regulatory T cells and macrophages. Immunotherapy and chemotherapy response evaluation revealed patients with a high TRP score demonstrated well reactions to immune checkpoint inhibitors (ICIs) and sorafenib. TRP score, TNM stage, and cancer type were brought into the combined nomogram with optimum prediction.
Our research provided dependable and simplified methods for patients with HCC to assess tumors' susceptibility to TACE refractoriness and prognosis and guide patients' clinical therapy choices.
经导管动脉化疗栓塞术(TACE)是治疗肝细胞癌(HCC)的有效方法。然而,许多患者对 TACE 反应不佳,导致预后不良。因此,寻找新的生物标志物来预测 TACE 耐药的发生和预后成为 HCC 治疗领域的研究重点之一。
基于微阵列数据集和高通量测序数据集,通过差异表达分析确定与 TACE 耐药相关的基因(TRGs)。LASSO 和 Cox 回归用于构建 TACE 耐药诊断评分(TRD 评分)和预后评分(TRP 评分),并在外部数据集验证其准确性。通过基因集变异分析和基因本体论分析 TRP 评分的功能相关性。使用 CIBERSORT 和 IMMUNCELL AI 算法分析两个评分与免疫活性的相关性。我们进一步对不同 TRP 评分组的免疫治疗和靶向药物疗效进行了分析。此外,通过整合各种独立的预后因素构建了一个列线图,并在不同数据集验证了其有效性。
我们结合 GSE104580 和 TCGA 数据集鉴定了 487 个 TRGs。然后筛选出四个新的 TRGs(TTK、EPO、SLC7A11 和 PON1)构建 TRD 评分和 TRP 评分模型,两个评分在外部数据集均具有良好的预测能力。高 TRP 评分的肿瘤表现出免疫抑制表型,更多的调节性 T 细胞和巨噬细胞浸润。免疫治疗和化疗反应评估表明,高 TRP 评分的患者对免疫检查点抑制剂(ICIs)和索拉非尼反应良好。TRP 评分、TNM 分期和癌症类型被纳入联合列线图,具有最佳预测能力。
本研究为评估 HCC 患者肿瘤对 TACE 耐药性和预后的敏感性以及指导患者的临床治疗选择提供了可靠且简化的方法。